92 related articles for article (PubMed ID: 15629263)
21. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
22. [Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial].
Fang LZ; Liang X; Zhang JQ; Liu L; Fu WP; Zhao ZH; Dai LM
Zhonghua Jie He He Hu Xi Za Zhi; 2008 Nov; 31(11):811-4. PubMed ID: 19080533
[TBL] [Abstract][Full Text] [Related]
23. Salbutamol improves markers of epithelial function in mice with chronic allergic pulmonary inflammation.
Toledo AC; Arantes-Costa FM; Macchione M; Saldiva PH; Negri EM; Lorenzi-Filho G; Martins MA
Respir Physiol Neurobiol; 2011 Jul; 177(2):155-61. PubMed ID: 21443970
[TBL] [Abstract][Full Text] [Related]
24. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
25. Mucociliary interaction in vitro: effects of physiological and inflammatory stimuli.
Seybold ZV; Mariassy AT; Stroh D; Kim CS; Gazeroglu H; Wanner A
J Appl Physiol (1985); 1990 Apr; 68(4):1421-6. PubMed ID: 1971819
[TBL] [Abstract][Full Text] [Related]
26. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility.
Bouros D; Kottakis J; Le Gros V; Overend T; Della Cioppa G; Siafakas N
Curr Med Res Opin; 2004 May; 20(5):581-6. PubMed ID: 15140323
[TBL] [Abstract][Full Text] [Related]
27. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
Kardos P; Wencker M; Glaab T; Vogelmeier C
Am J Respir Crit Care Med; 2007 Jan; 175(2):144-9. PubMed ID: 17053207
[TBL] [Abstract][Full Text] [Related]
28. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.
Stockley RA; Whitehead PJ; Williams MK
Respir Res; 2006 Dec; 7(1):147. PubMed ID: 17196106
[TBL] [Abstract][Full Text] [Related]
29. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
Gupta RK; Chhabra SK
Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
[TBL] [Abstract][Full Text] [Related]
31. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
33. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
34. Role of mucus and cilia in nasal mucociliary clearance in healthy subjects.
Lioté H; Zahm JM; Pierrot D; Puchelle E
Am Rev Respir Dis; 1989 Jul; 140(1):132-6. PubMed ID: 2751159
[TBL] [Abstract][Full Text] [Related]
35. N-Acetylcysteine and mucociliary activity in mammalian airways.
Iravani J; Melville GN; Horstmann G
Arzneimittelforschung; 1978; 28(2):250-4. PubMed ID: 580387
[TBL] [Abstract][Full Text] [Related]
36. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
37. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
38. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
39. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
40. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
